89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

• Published in: Nature medicine Vol. 24; no. 12; pp. 1852 - 1858
• Main Authors: Bensch, Frederike, Elly L van der Veen, Marjolijn N Lub-de Hooge, Jorritsma-Smit, Annelies, Boellaard, Ronald, Kok, Iris C, Oosting, Sjoukje F, Schröder, Carolina P, T Jeroen N Hiltermann, Anthonie J van der Wekken, Groen, Harry J M, Kwee, Thomas C, Elias, Sjoerd G, Gietema, Jourik A, Sandra Sanabria Bohorquez, de Crespigny, Alex, Simon-Peter, Williams, Mancao, Christoph, Brouwers, Adrienne H, Fine, Bernard M, Elisabeth G E de Vries
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group 01.12.2018
• Subjects: Antibodies; Apoptosis; Biomarkers; Biopsy; Cancer; Cell death; Emission analysis; Feasibility studies; Gene sequencing; Immunohistochemistry; Immunotherapy; Lesions; Lymphoid tissue; Medical imaging; Monoclonal antibodies; Patients; PD-1 protein; PD-L1 protein; Positron emission; Positron emission tomography; Predictions; Proteins; Ribonucleic acid; RNA; Targeted cancer therapy; Tomography; Tumors; Zirconium; Zirconium isotopes

Programmed cell death protein-1/ligand-1 (PD-1/PD-L1) blockade is effective in a subset of patients with several tumor types, but predicting patient benefit using approved diagnostics is inexact, as some patients with PD-L1-negative tumors also show clinical benefit1,2. Moreover, all biopsy-based te...